Blueprint Medicines Corporation (BPMC)
NEGATIVEFundamental
~0
Price
$-
Market Cap
-
Part 1 · What the company is worth
Overview
No description available.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Limited financial data available (0% of metrics). Scores may not accurately reflect this company's fundamentals.
Balance Sheet & Liquidity
Revenue
-
Net Income
-
Free Cash Flow
-
Total Equity
-
Total Liabilities
-
Current Ratio
2.85
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Valuation Metrics
P/E Ratio
-
ROE
-48.9%
P/B Ratio
-
P/FCF
-
Gross Margin
-
ROIC
-
Profitability Radar
Value Creation (Economic Moat)
ROIC
-
WACC
12.0%
ROIC − WACC
-
Fundamental Analysis Criteria
Passed (0)
Failed (0)
Unavailable (1)
- Error fetching data
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Buying back shares. Shareholder friendly
Governance
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for BPMC, sourced from Markets Gazette.
- 3/16/2026POSITIVEThis $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
Arcellx, a clinical-stage biotechnology company focused on cell-based immunotherapies for cancer, experienced a significant market event following a takeover deal involving Gilead Sciences. While the article doesn't explicitly state Arcellx's stock ticker, it highlights a potential 77% one-day surge, suggesting a substantial premium for Arcellx shareholders. This development underscores the value of Arcellx's proprietary platforms in addressing unmet needs in oncology, making it an attractive acquisition target. Investors in the biotech sector should monitor such M&A activities as indicators of innovation and potential returns.
via Markets Gazette